Bladder cancer arise and progress along two distinctive pathways. The first of these is often preceded by simple and papillary hyperplasia and exhibits a tumour morphology that is low-grade, superficial and papillary. Papillary carcinoma has a tendency to recur locally, but rarely invades and metastasizes. These tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. The second tumour pathway is characterized by high-grade muscle-invasive tumours, which either originate from flat carcinoma in situ (CIS)/severe dysplasia or arise de novo. Over half of these tumours show defects in the tumour suppressors p53 and/or the retinoblastoma protein (RB) genes and pathways, and over 50% of these tumours progress to local and distant metastases. Some of the cell cycle-related molecules show evidence of epigenetic modulation through aberrant promoter hypermethylation in invasive bladder cancer. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).
kegg.pathway:hsa05219
RO:0002162
)
BFO:0000051
)
ncbigene:3265
ncbigene:1869
ncbigene:5894
ncbigene:1956
ncbigene:1029
ncbigene:3845
ncbigene:1950
ncbigene:1026
ncbigene:1890
ncbigene:7422
ncbigene:369
ncbigene:7424
ncbigene:7423
ncbigene:5228
ncbigene:3576
ncbigene:595
ncbigene:2064
ncbigene:4313
ncbigene:4312
ncbigene:5605
ncbigene:9252
ncbigene:673
ncbigene:4318
ncbigene:5604
ncbigene:1019
ncbigene:4193
ncbigene:5925
ncbigene:2277
ncbigene:11186
ncbigene:7157
ncbigene:1871
ncbigene:2261
ncbigene:1870
ncbigene:4893
ncbigene:5595
ncbigene:1613
ncbigene:23604
ncbigene:1612
ncbigene:7057
ncbigene:4609
ncbigene:999
ncbigene:5594